EpsteinJB, SchubertMM. Oropharyngeal mucositis in cancer therapy. Review of pathogenesis, diagnosis, and management. Oncology (Williston Park), 2003; 17:1767–1779discussion 1779–1782, 1791–1792.
2.
ScullyC, EpsteinJ, SonisS. Oral mucositis: A challenging complication of radiotherapy, chemotherapy, and radiochemotherapy. Part 2: Diagnosis and management of mucositis. Head Neck, 2004; 26:77–84.
3.
BensingerW, SchubertM, AngKK, BrizelD, BrownE, EilersJG, EltingL, MittalBB, SchattnerMA, SpielbergerR, TreisterNS, TrottiAM3rd. NCCN Task Force Report: Prevention and management of mucositis in cancer care. J Natl Compr Canc Netw, 2008; 6,Suppl 1:S1–S21quiz S22–24.
4.
TzchentekeTM. Behavioral pharmacology of buprenorphine, with a focus on preclinical models of reward and addiction. Psychopharmacology, 2002; 161:1–16.
5.
KressHG. Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine. Eur J Pain, 2009; 13:219–230.
6.
LikarR, GriessingerN, SadjakA, SittlR. Transdermal buprenorphine for treatment of chronic tumor and non-tumor pain [in German]Wien Med Wochenschr, 2003; 153:317–322.
7.
SittlR. Transdermal buprenorphine in cancer pain and palliative care. Palliat Med, 2006; 20,Suppl 1:s25–30.
8.
PaceMC, PassavantiMB, GrellaE, MazzarielloL, MaistoM, BarbarisiM, BaccariE, SansoneP, AurilioC. Buprenorphine in long-term control of chronic pain in cancer patients. Front Biosci, 2007; 12:1291–1299.
9.
CerchiettiL, NaviganteAH, BonomiMR, ZaderajkoMA, MenéndezPR, PoganyCE, RothBM. Effect of topical morphine for mucositis-associated pain following concomitant chemoradiotherapy for head and neck carcinoma. Cancer, 2002; 95:2230–2236.
